Recombinant viral vector vaccines
Recombinant viral vector vaccines use live, modified viruses to deliver genes that encode antigens from a target pathogen allowing the immune system to produce a protective response. Live recombinant viral vectored vaccines have become a central strategy in the fight against emerging infectious diseases, from COVID-19 to Ebola. Their dual ability to induce both humoral and cellular immunity makes them a valuable tool in modern vaccinology.
As a relatively new vaccine platform, recombinant viral vector vaccines bring unique analytical challenges that require specialised analytical expertise. From genome identity to infectivity, purity and integrity, each batch must meet rigorous quality expectations to ensure both safety and efficacy for the patients.
At Quality Assistance, we support your recombinant viral vector vaccine development with dedicated, phase-appropriate analytical solutions. Our experts help you demonstrate product identity, control critical quality attributes and ensure consistency through all your development process.
Recombinant viral vectored vaccines specific services
To help you characterise these complex rAAV vaccines, we apply a full set of analytical techniques tailored to their unique structure and mechanism of action:
| Viral vector aggregates | SEC-(U)HPLC (UV, RI, MALS) / AF4 (UV, RI, MALS) / DLS / Imaging Particle Analysis |
|---|---|
| Full / Empty capsids | cGE / IEX (UV) / SEC-(U)HPLC (UV, RI, MALS) / SoloVPE |
| Vector particle concentration | qPCR / IEX / UV spectroscopy |
|---|---|
| Total protein | UV spectroscopy / (U)HPLC (UV) |
| Capsid concentration | ELISA / SPR (Biacore) / BLI (Octet) / Gyrolab / MA-DLS |
General testing solutions for your vaccine programme
Beyond specific assays, recombinant viral vector vaccines require a full suite of analytical services to ensure product safety. From sterility and endotoxin testing to long-term stability studies and batch release under GMP conditions, these evaluations are essential to meet regulatory expectations.
At Quality Assistance, our vaccine testing capabilities are designed to support all vaccine types through harmonised, phase-appropriate strategies.
We cover all major vaccine technologies
Extending viral vector expertise beyond vaccines
The technologies and scientific expertise used to characterise recombinant viral vector vaccines are also applicable to gene therapy product.
This synergy allows us to support your development with consistent, compliant analytics whether you're targeting infectious diseases or genetic disorders.
Related services
Ready for the next step of your development ?
Developing recombinant viral vector vaccines requires integrated expertise in molecular biology and advanced analytics. At Quality Assistance, we centralise all analytical capabilities on a single site, ensuring clarity, compliance and confidence throughout your development journey.
Talk to our experts today to design an analytical plan for your viral vector vaccine and accelerate its path to approval.
Get in touch with our team of experts